Medicaid Reimbursement Decline: Impacts on Mohs Surgery Accessibility

Recent analysis on Medicaid reimbursements for Mohs micrographic surgery reveals a concerning decline, posing challenges for patient access and care quality in managing nonmelanoma skin cancers.

A study published in the Archives of Dermatological Research sheds light on shifting trends in Medicaid reimbursements for Mohs surgery from 2016 to 2022. Conducted by researchers from prominent institutions such as the University of Nevada, Mayo Clinic, Stanford University, and the University of California, the research reveals an inflation-adjusted payment decline of 18.33% for initial surgery stages and 25.52% for subsequent stages.

State Disparities and Medicaid Expansion

The study highlights noticeable reimbursement discrepancies between states with different Medicaid expansion statuses under the Affordable Care Act. States adopting Medicaid expansion saw a 5.71% decrease in payments, contrasting with a 5.80% increase in non-expansion states. These financial inconsistencies might deter surgeons in expansion states from accepting Medicaid, threatening patient access.

Medicaid expansion extends coverage to low-income individuals, intended to improve care access. However, these differing reimbursement trends suggest a financial model that may inadvertently discourage healthcare providers from participating in Medicaid, particularly where payment cuts coincide with higher demand.

Financial Pressures and Patient Access

Researchers used linear regression models, adjusting for inflation to accurately assess reimbursement trends' economic impact. These trends reveal significant financial pressures on states managing increased enrollments, with many resorting to low reimbursement rates to balance budgets. Such policies can hinder patients' access to essential procedures like Mohs surgery.

“Low Medicaid reimbursement rates influence dermatologic surgeons' willingness to accept Medicaid patients, creating access disparities.”

Research Study, University of Nevada

Historically, Medicaid rates have lagged behind Medicare reimbursements, further complicating the situation as skin cancer incidence continues to rise. These reimbursement declines particularly affect complex surgery stages necessary for removing intricate tumors.

Implications for Policy and Care Availability

As policymakers evaluate the balance between Medicaid expansion benefits and sustaining provider payments, this study underscores the urgent need for adjusted fee schedules. The goal should be to ensure that expanded insurance truly equates to accessible and quality treatment options for patients.

By addressing these reimbursement issues, the health system can better support both providers and patients, ensuring broader access to essential cancer treatments like Mohs surgery. As the healthcare landscape evolves, the priority remains aligning Medicaid policy with healthcare accessibility and effectiveness.